BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fludase: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 177 evaluable patients with PCR-confirmed influenza infection showed that once-daily 10 mg DAS181 for 3 days significantly reduced viral load in respiratory secretions, the primary endpoint, over the first 24 hours after treatment (p<0.002), the first 48 hours (p<0.009) and from days 1-5 vs....

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >